We restore endothelial cell function.
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.
Pantherna is based in Hennigsdorf (Brandenburg) close to Berlin, Germany.
“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million in a successful seedfinancing round. The start-up presents a proprietary, innovative technology platform for the development of novel mRNA therapeutics to treat Acute Respiratory Distress Syndrome (ARDS), a severe lung disease. The funds will be used to advance R&D activities and hire additional scientific staff. Investors are the High-Tech Gründerfonds (HTGF), European Business Angel Prof. Detlev Riesner as well as the European Investment Fund and the State of Brandenburg. [...]
Get in touch
Pantherna Therapeutics GmbH
Telephone: +49(0)3302-202 240-0
Telefax: +49(0)3302-202 240-1
Managing Directors: Dr. Klaus Giese, Dr. Jörg Kaufmann, Dr. Gerrit Maass